Jimmy Rosen is President & CEO of Artizan Bioscience. Artizan was established to further the research & development pursuits of Yale faculty members Noah Palm and Richard Flavell. Prior to helping found Artizan, Jimmy led the program related venture capital investment function for the Bill & Melinda Gates Foundation in Seattle.
From 2005-2015, Jimmy was with Intersouth Partners, where he was a Partner on the life sciences investment team. Prior to joining Intersouth, he spent 15 years in clinical, research and financial positions in the health care and biotechnology sectors.
Jimmy’s research experience includes programs at the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill, the National Cancer Institute, Duke University Medical Center and its Comprehensive Cancer Center. He also managed and monitored clinical trials at a privately held contract research organization, which led to FDA-approved products. Jimmy spent several years as an equity research analyst at Brean Murray & Co., covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. Prior to his research and Wall Street functions, he spent five years in Emergency Medical Services as a mountain search & rescue and ambulance medic.
Jimmy currently serves on numerous boards and advisory committees, including Chairman of the Public Health Foundation Board and Dean’s Advisory Council for the Gillings School of Global Public Health at the University of North Carolina, the board of Southeast BIO, and the Oversight Committee for the Duke-Coulter Translational Partners Program. He is also a frequent lecturer at Duke, UNC and NC State University.
Jimmy holds a B.A. from Duke University and an M.B.A. from UNC-Chapel Hill’s Kenan-Flagler School of Business where he was a Carolina Venture Fellow and recipient of the Frank Hawkins Kenan Award for Excellence. He received his M.S.P.H. from the UNC School of Public Health. In 2010 Jimmy was awarded the Eisenhower Fellowship for which he designed and executed a program to evaluate the prospects for health care innovation in China and Southeast Asia.